Attention-Deficit/Hyperactivity Disorder (ADHD)

Houston, TX

8 Attention-Deficit/Hyperactivity Disorder (ADHD) Trials near Houston, TX

Power is an online platform that helps thousands of Attention-Deficit/Hyperactivity Disorder (ADHD) patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

Centanafadine for ADHD

Houston, Texas
This trial aims to test the safety and tolerability of a daily ADHD medication in children and teens aged 4-17. The medication releases its effects slowly over the day to help manage symptoms consistently. HLD200 is a form of methylphenidate designed to provide benefits from morning until evening.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:4 - 18

680 Participants Needed

SPN-812 ER for ADHD

Houston, Texas
Open label extension, long-term multicenter study of safety and efficacy of SPN-812 in pediatric ADHD patients
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:4 - 18

1400 Participants Needed

tRNS for ADHD

Houston, Texas
A randomized, sham-controlled, double-blind clinical trial to examine the safety and effectiveness of tRNS on unmedicated pediatric patients (7-12 years) with ADHD. Subjects will undergo either tRNS or sham treatment for 10 days during a two-week period in a home-simulated environment. Each treatment session is 20 minutes, during which their attention will be maintained using a software game.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:7 - 12

146 Participants Needed

B-SAFE Program for Childhood Sleep Disorders

Houston, Texas
Sleep disturbances are pervasive and impairing among children who spend time in foster care but not a single prevention or intervention program for this fragile group targets sleep health. Poor sleep undermines effective self-regulation and stable biological rhythms, amplifying the negative impacts of early adversity/trauma on immediate and long-term functioning. Consistent with evidence that optimizing sleep is critical for trauma recovery, the investigators will adapt cognitive-behavioral treatment for pediatric insomnia for children placed in or adopted from foster care to evaluate child outcomes and target mechanism engagement and explore implementation barriers and supports.
No Placebo Group

Trial Details

Trial Status:Recruiting
Age:6 - 10

60 Participants Needed

Videolaryngoscope vs Regular Laryngoscope for Infant Intubation

Houston, Texas
Nasotracheal Intubation with Videolaryngoscopy versus Direct Laryngoscopy in Infants (NasoVISI) Trial is a prospective randomized multicenter study. The study will be conducted at 8 centers in the United States. It is expected that approximately 700 subjects enrolled to product 670 evaluable subjects.The randomization is 1:1 naso tracheal intubation with the Storz C-Mac Video Videolaryngoscopy (VL) or the Standard Direct Laryngoscope (DL). The primary objective is to compare the nasotracheal intubation (NTI) first attempt success rate using VL vs. DL in infants 0-365 days of age presenting for cardiothoracic surgery and cardiac catheterizations.
No Placebo Group

Trial Details

Trial Status:Recruiting
Age:1+

1400 Participants Needed

Azstarys® for ADHD

Bellaire, Texas
The is a multicenter, dose-optimized, open-label, safety/ tolerability and pharmacokinetic (PK) study with Azstarys® in children 4 and 5 years of age with attention-deficit/hyperactivity disorder (ADHD). The primary objective is to determine the safety and tolerability of treating children 4 and 5 years-of-age with ADHD with Azstarys® for up 12 months. Approximately 100 subjects will be enrolled. Approximately 20 sites will participate.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 4
Age:4 - 5

123 Participants Needed

SPN-812 for ADHD

Bellaire, Texas
This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4
Age:48 - 69

286 Participants Needed

TAK-503 for ADHD

The Woodlands, Texas
The main aim of this study is learn more about long-term TAK-503 treatment in children and teenagers with ADHD for whom earlier stimulant treatment did not work. The study has two parts (A and B). In Part A, participants will take tablets of TAK-503, atomoxetine or placebo and in Part B TAK-503 tablets.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 4
Age:6 - 17

397 Participants Needed

Why Other Patients Applied

"ADHD has been a trait that I consider as a blessing, as it can make me more creative, but I struggle with focusing and forgetting things... it affects my work. Looking for a new medicine to try will hopefully help me to get better along with my day-to-day activities and job."

QM
ADHD PatientAge: 27

"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

FF
ADHD PatientAge: 31

"I have been living with untreated ADHD my entire life life. It’s getting to the point where most days can be quite debilitating and I experience adhd paralysis on a regular basis. My PCP won’t even listen to my concerns and I don’t know where to turn to get help. Hoping to get better care this way."

VN
ADHD PatientAge: 49

"I am currently taking Mydayis. I've used vyvanse, adderall, strattera, concerta. I have struggled with this disorder my whole life. At 43, I am attempting to go to law school. I would like to have a different experience than I had in undergrad. I suffer from poor executive dysfunction. Impulsively, and lack of focus. ADHD has impacted every part of my life. "

LX
ADHD PatientAge: 44

"Executive function difficulties impact my daily life, and I have not found relief through traditional approaches. I dislike how standard stimulants make me feel. I'm very interested in trying the latest research treatments."

FF
ADHD PatientAge: 35

Know someone looking for new options? Spread the word

Match to a Trial